Merck KGaA’s Erbitux Gets Green Light for Head Cancer

FRANKFURT, Oct 24 (Reuters) - A committee of experts advising the European Commission said on Friday it backed Merck KGaA's Erbitux drug for a second use to combat head and neck cancer, bolstering its sales potential in the region.